Benjamin Hohl - Net Worth and Insider Trading
Benjamin Hohl Net Worth
The estimated net worth of Benjamin Hohl is at least $476,790 dollars as of 2025-07-04. Benjamin Hohl is the CHIEF FINANCIAL OFFICER of Enliven Therapeutics Inc and owns about 23,000 shares of Enliven Therapeutics Inc (ELVN) stock worth over $476,790. Details can be seen in Benjamin Hohl's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Benjamin Hohl has not made any transactions after 2025-06-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Benjamin Hohl
Benjamin Hohl Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Benjamin Hohl owns 1 companies in total, including Enliven Therapeutics Inc (ELVN) .
Click here to see the complete history of Benjamin Hohl’s form 4 insider trades.
Insider Ownership Summary of Benjamin Hohl
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| ELVN | Enliven Therapeutics Inc | 2025-06-27 | Chief Financial Officer |
Benjamin Hohl Latest Holdings Summary
Benjamin Hohl currently owns a total of 1 stock. Benjamin Hohl owns 23,000 shares of Enliven Therapeutics Inc (ELVN) as of June 27, 2025, with a value of $476,790.
Latest Holdings of Benjamin Hohl
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics Inc | 2025-06-27 | 23,000 | 20.73 | 476,790 |
Holding Weightings of Benjamin Hohl
Benjamin Hohl Form 4 Trading Tracker
According to the SEC Form 4 filings, Benjamin Hohl has made a total of 31 transactions in Enliven Therapeutics Inc (ELVN) over the past 5 years, including 0 buys and 31 sells. The most-recent trade in Enliven Therapeutics Inc is the sale of 3,250 shares on June 27, 2025, which brought Benjamin Hohl around $67,958.
Insider Trading History of Benjamin Hohl
- 1
Benjamin Hohl Trading Performance
Benjamin Hohl Ownership Network
Ownership Network List of Benjamin Hohl
Ownership Network Relation of Benjamin Hohl
Benjamin Hohl Owned Company Details
What does Enliven Therapeutics Inc do?
Who are the key executives at Enliven Therapeutics Inc?
Benjamin Hohl is the Chief Financial Officer of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include director & Chief Scientific Officer Joseph P Lyssikatos , director & President and CEO Samuel Kintz , and Chief Operating Officer Anish Patel .
Enliven Therapeutics Inc (ELVN) Insider Trades Summary
Over the past 18 months, Benjamin Hohl made 29 insider transaction in Enliven Therapeutics Inc (ELVN) with a net sale of 110,314. Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 242,342 shares made by Samuel Kintz , a net sale of 241,847 shares made by Joseph P Lyssikatos , and a net sale of 156,793 shares made by Anish Patel .
In summary, during the past 3 months, insiders sold 107,751 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 107,751 shares. During the past 18 months, 4,286,790 shares of Enliven Therapeutics Inc (ELVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,286,790 shares.
Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Enliven Therapeutics Inc Insider Transactions
Benjamin Hohl Mailing Address
Above is the net worth, insider trading, and ownership report for Benjamin Hohl. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Benjamin Hohl's mailing address is: Boulder Co 80301.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
